FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Water, 1,2-Hexanediol, Hydrogenated Lecithin, Glutathione, Disodium EDTA, Ceramide NP, Methylpropanediol, Glycerin, Niacinamide, Butylene Glycol, Sodium Ascorbyl Phosphate, Pyridoxine, Riboflavin, Biotin, Cyanocobalamin, Ascorbic Acid, Thiamine HCl, Folic Acid, Propanediol, Glycereth-26, Dipropylene Glycol, Sodium Hyaluronate, Polyglycerin-3, Glyceryl Acrylate/Acrylic Acid Copolymer, PVM/MA Copolymer, Carbomer, Arginine, Allantoin, Polyglyceryl-10 Laurate, Coptis Japonica Root Extract, Ethylhexylglycerin, Xanthan Gum, Panthenol, Hippophae Rhamnoides Water, Methyl Diisopropyl Propionamide, Fragrance, Sodium Polyacrylate, Acetyl Glucosamine, 3-O-Ethyl Ascorbic Acid, Lecithin, Polysorbate 20, Retinol, Tocopherol
Price: 75 Duration: 30 minutes Glutathione Mini IV Infusion (600mg) Delivered intravenously, the Glutathione Mini IV provides direct bloodstream delivery and additional fluid support
Irianto, J., Xia, Y., Pfeifer, C
Pharmacological properties of furoxans and benzofuroxans: recent developments
This interaction promotes M2 macrophage polarization, enhancing pro-tumorigenic phenotypes (68)